The primary mission of the Molecular Hematopathology Laboratory at NewYork-Presbyterian/Weill Cornell Medicine is to provide the best clinical molecular diagnostic services for the clinicians and pathologists providing care to patients with hematologic malignancies. For many years, this laboratory has been developing and performing molecular-based tests to aid in the diagnosis and management of hematologic cancers, and has worked closely with hematopathologists in the Division of Hematopathology and clinical hematologists in the Department of Medicine to provide excellent patient care. The laboratory is CLIA-certified and accredited by the College of American Pathologists.
Approximately 1,700 tests are performed in the Molecular Hematopathology Laboratory each year.
Please click here to download full test menu and sample requirements.
The Molecular Hematopathology Laboratory is currently expanding its test menu. Its molecular hematopathologists are working on standardization of its quantitative BCR-ABL testing on the International Scale, which standardizes quantitative BCR-ABL1 measurements across tests and laboratories and harmonizes definition of treatment response, allowing meaningful and easy interpretation of test results. The laboratory is also on the verge of employing next-generation sequencing for gene mutational profiling to assess prognostic factors in leukemias and lymphomas.
In addition, the Molecular Hematopathology Laboratory is the site for several translational research projects in hematologic malignancies — including tumor suppressors, microRNAs, oncogenic viruses, targeted drug therapy, biomarker development, and clonal evolution — and has actively contributed to peer-reviewed publications. The attending pathologists and staff members in the laboratory also educate pathology residents and fellows through laboratory rotations and meetings, a journal club, and interdisciplinary conferences.